Category Archives: Public Policy

Latest From Public Policy

Patent Trolls and Patent Litigation: The GAO Weighs In

shutterstock_26191726

Patent troll litigation alarmist were likely disappointed by the GAO report.  While the public discourse may have already concluded that patent trolls have laid waste to the innovative landscape by creating a patent litigation crisis, the GAO report does not find much evidence to support such claims. Patent troll litigation is not running rampant.  The GAO analyzed a sample of 500 patent infringement lawsuits from 2007 to 2011 and found that companies that make products (operating Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , ,

What a Patent is Not

shutterstock_2103563

‘Patent trolls.’  ‘Patients over patents.’  ‘Do Not Patent My Genes.’  ‘Patents ate my baby.’  Ok, so I made the last one up.  The emphasis on patents in the public discourse has reached a new high.  Yet, many commentators get the basics wrong.  Here are a few things that a patent is not. A patent is not ownership of a thing, whether it is life, genes, viruses, computer code, or any other animate or inanimate object.  Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , ,

California Continues Responsible Support for Interchangeability of Biologic Drugs

State Capitol

Yesterday, California’s State Assembly Committee on Appropriations took another decisive step when they unanimously voted in support of the revised SB 598 by recommending it back to the full Assembly after minor modifications. This is another important step taken by the California State Legislature to ensure patients and physicians who are managing chronic conditions are made fully aware of which biologic drug is ultimately administered by the pharmacist. When battling a serious disease, patients, physicians Read More >

Public Policy  |  Leave a comment  |  Email This Post
Tags: , , , ,

Fresenius v. Baxter: BIO files Amicus Brief in Federal Circuit

shutterstock_1092009

The Biotechnology Industry Organization filed an amicus brief at the Federal Circuit in the case of Fresenius v. Baxter: BIO is concerned that the panel decision could have a number of unintended consequences, such as incentivizing defendants (or declaratory judgment plaintiffs) to employ dilatory tactics in the federal courts while re-arguing already-decided issues under claim construction more favorable to the patent challenger and lower burden-of-proof standards in the PTO.  Courts and parties may be forced Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , ,

TTIP: Global Regulatory Cooperation and Convergence

Moving Inside the Beltway: Brief Health Roundup

The Transatlantic Trade and Investment Partnership (TTIP) initiative holds tremendous promise for the long-term competitiveness of the Transatlantic economy by supporting research and development of innovative technologies. A concerted effort through the TTIP to unleash the potential of biotechnology in the Transatlantic economy can help bring innovative products to consumers, create jobs, and improve economic prospects on both sides of the Atlantic. The recent (TTIP) negotiations focus on several principles that BIO promotes to boost Read More >

Public Policy  |  Leave a comment  |  Email This Post
Tags: , , , ,